The Canadian biotechnology company, Oncolytics Biotech. Inc., has recently opened a Phase 1b trial of its proprietary drug Reolysin in combination with Velcade® and dexamethasone for relapsed and/or refractory myeloma patients. Reolysin is a variant of the reovirus (Respiratory Enteric Orphan Virus) that is known to infect and selectively destroy cancer cell, particularly those with one or more mutations in the RAS signalling pathway. Such cells have an aberrant antiviral response and are unable to prevent the virus from replicating, allowing it to multiply to an extent that is fatal to the infected cell. The trial is aiming to evaluate the safety, optimum dose and efficacy of Reolysin when given alongside Velcade and dexamethasone.